This website does readability filtering of other pages. All styles, scripts, forms and ads are stripped. If you want your website excluded or have other feedback, use this form.

Novartis shells out up to $1B to test GSK's Arzerra in MS | FiercePharma

Skip to main content

Twitter LinkedIn Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe


Novartis shells out up to $1B to test GSK's Arzerra in MS

Thanks to the companies' recent multi-billion-dollar asset swap, Novartis ($NVS) already has the rights to former GlaxoSmithKline ($GSK) drug ofatumumab's cancer applications. But now, it's forking over up to $1 billion to gain full control of the med--currently marketed as Arzerra--and to test it as a therapy for multiple sclerosis. More

Suggested Articles


J&J recalls one lot of talc, and investors wipe away billions

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

by Eric Sagonowsky Oct 18, 2019 11:09am Manufacturing

Teva recalls tainted Zantac generics in the U.K.

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

by Eric Palmer Oct 18, 2019 10:50am Marketing

Pfizer's tafamidis poised for 'a decisive beat': analyst

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.

by Angus Liu Oct 18, 2019 11:47am